Gewählte Publikation:
SHR
Neuro
Krebs
Kardio
Lipid
Stoffw
Microb
Kluth, LA; Abdollah, F; Xylinas, E; Rieken, M; Fajkovic, H; Sun, M; Karakiewicz, PI; Seitz, C; Schramek, P; Herman, MP; Becker, A; Loidl, W; Pummer, K; Nonis, A; Lee, RK; Lotan, Y; Scherr, DS; Seiler, D; Chun, FK; Graefen, M; Tewari, A; Gönen, M; Montorsi, F; Shariat, SF; Briganti, A.
Pathologic nodal staging scores in patients treated with radical prostatectomy: a postoperative decision tool.
Eur Urol. 2014; 66(3):439-446
Doi: 10.1016/j.eururo.2013.06.041
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
-
Pummer Karl
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
-
Nodal metastasis is the strongest risk factor of disease recurrence in patients with localized prostate cancer (PCa) treated with radical prostatectomy (RP).
To develop a model that allows quantification of the likelihood that a pathologically node-negative patient is indeed free of nodal metastasis.
Data from patients treated with RP and pelvic lymph node dissection (PLND; n=7135) for PCa between 2000 and 2011 were analyzed. For external validation, we used data from patients (n=4209) who underwent an anatomically defined extended PLND.
RP and PLND.
We developed a novel pathologic (postoperative) nodal staging score (pNSS) that represents the probability that a patient is correctly staged as node negative based on the number of examined nodes and the patient's characteristics.
In the development and validation cohorts, the probability of missing a positive node decreases with an increasing number of nodes examined. Whereas in pT2 patients, a 90% pNSS was achieved with one single examined node in both the development and validation cohort, a similar level of nodal staging accuracy was achieved in pT3a patients by examining five and nine nodes, respectively. The pT3b/T4 patients achieved a pNSS of 80% and 70% when 17 and 20 nodes in the development and validation cohort were examined, respectively. This study is limited by its retrospective design and multicenter nature. The number of nodes removed was not directly correlated with the extent/template of PLND.
Every patient needs PLND for accurate nodal staging. However, a one-size-fits-all approach is too inaccurate. We developed a tool that indicates a node-negative patient is indeed free of lymph node metastasis by evaluating the number of examined nodes, pT stage, RP Gleason score, surgical margins, and prostate-specific antigen. This tool may help in postoperative decision making.
Copyright © 2013 European Association of Urology. Published by Elsevier B.V. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
-
Aged -
-
Aged, 80 and over -
-
Decision Support Techniques -
-
False Negative Reactions -
-
Humans -
-
Lymph Node Excision -
-
Lymph Nodes - pathology
-
Lymph Nodes - surgery
-
Lymphatic Metastasis -
-
Male -
-
Middle Aged -
-
Neoplasm Staging -
-
Pelvis -
-
Postoperative Period -
-
Probability -
-
Prostatectomy -
-
Prostatic Neoplasms - pathology
-
Prostatic Neoplasms - surgery
-
Retrospective Studies -
- Find related publications in this database (Keywords)
-
Prostate cancer
-
Pelvic lymph node dissection
-
Lymph node metastasis
-
Extended lymph node dissection
-
Nodal yield